Mycophenolate mofetil:
Mycophenolic acid:
Contraindicated in:
Use Cautiously in:
CV: edema, hypertension, hypotension, tachycardia.
Derm: rash.
Endo: hyperglycemia.
F and E: hyperkalemia, hypocalcemia, hypokalemia, hypomagnesemia.
GI: anorexia, constipation, diarrhea, nausea, vomiting, abdominal pain, GI BLEEDING.
GU: renal impairment.
Hemat: leukocytosis, leukopenia, thrombocytopenia, anemia, pure red cell aplasia.
Metab: hypercholesterolemia.
Neuro: anxiety, confusion, dizziness, headache, insomnia, paresthesia, sedation, tremor, PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML).
Misc: fever, infection (including activation of latent viral infections such as Polyomavirus-associated nephropathy or Hepatitis B/C), acute inflammatory syndrome, MALIGNANCY.
Drug-Drug:
(Generic available)
Mycophenolate Mofetil
Mycophenolic Acid
Mycophenolate Mofetil
Kidney TransplantationRenal Impairment
Mycophenolic Acid
Mycophenolate mofetil and mycophenolic acid should not be used interchangeably without the advice of a health care professional.
Kidney TransplantationAbsorption: Following oral and IV administration, mycophenolate mofetil is rapidly hydrolyzed to mycophenolic acid (MPA), the active metabolite. Absorption of enteric-coated mycophenolic acid (Myfortic) is delayed compared with mycophenolate mofetil (CellCept).
Distribution: Cross the placenta and enter breast milk.
Protein Binding: MPA: 97%.
Metabolism/Excretion: MPA is extensively metabolized; <1% excreted unchanged in urine. Some enterohepatic recirculation of MPA occurs.
Half-life: MPA: 8–18 hr.
(blood levels of MPA)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| mycophenolate mofetil-PO | rapid | 0.25–1.25 hr | N/A |
| mycophenolic acid | rapid | 1.5–2.75 hr | N/A |
NDC Code*